Citigroup Sets PA GOODDOCTOR (01833) Price Target at HK$18 with "Buy" Rating Following Strong 2025 Earnings Beat
Stock News
Mar 25
Citigroup has issued a research report stating that PA GOODDOCTOR (01833) achieved revenue of 5.468 billion yuan in 2025, representing a 14% year-on-year increase, with a net profit of 380 million yuan, surging 366% compared to the previous year. The full-year revenue met expectations, while the net profit exceeded market and the bank's own forecasts by 37% and 32%, respectively. The bank currently assigns a target price of HK$18 and a "Buy" rating. During the period, the gross profit margin improved from 31.7% in 2024 to 32.4%, and the net profit margin rose from 1.7% to 6.9%. Supported by AI empowerment and enhanced efficiency management, the adjusted net profit margin increased from 3.3% to 7.6%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.